Cronos Group Inc. (CRON) Earnings Call Transcript & Summary

November 12, 2024

Toronto Stock Exchange CA Health Care Pharmaceuticals earnings 19 min

Earnings Call Speaker Segments

Operator

operator
#1

Good morning, everyone. I'm Brianna, and I'll be serving as your conference operator for today. I'd like to extend a welcome to all of you to Cronos Group's 2024 Third Quarter Earnings Conference Call. This call is being recorded as of today. Right now, I'd like to hand things over to Anna Shlimak, our Chief Strategy Officer. Please go ahead.

Anna Shlimak

executive
#2

Thank you, Brianna, and I appreciate everyone being here as we go through Cronos' financial and business results for the third quarter of 2024. With me today are Mike Gorenstein, our Chairman, President and CEO, and James Holm, our CFO. This morning Cronos put out a news release with our financial results, and it has been filed on our EDGAR and SEDAR profile. You'll also find this information and the prepared remarks posted on our website in the Investor Relations section. Before handing things over to Mike, I want to remind everyone that during this call we may make forward-looking statements and refer to non-GAAP financial measures. Those forward-looking statements rest on management's current expectations and assumptions, and they carry risks and uncertainties that could make actual results differ materially from what those forward-looking statements project. The factors that could cause actual results to differ materially from expectations are laid out in detail in our earnings materials and in our SEC filings, which you can access on our website, and any forward-looking statements made during this call are qualified in their entirety by those documents. Details on non-GAAP financial measures, including reconciliations to U.S. GAAP, are also available in the earnings materials posted on our website. Finally, throughout this conference call we will be making statements about market share information, and unless otherwise stated, all market share data comes from Hifyre.

Anna Shlimak

executive
#3

We're going to give our prepared remarks at this point, and after that we'll open things up for a question-and-answer session. So with that said, I'll hand things over to Mike Gorenstein, who serves as Chairman, President and CEO of Cronos.

Mike Gorenstein

executive
#4

Thank you, Anna, and good morning to all of you. This quarter's results showed that the long-term strategy we've taken toward this industry is delivering returns. With revenue at a record level in the quarter and the disciplined way we manage operating expenses, we're proving we can grow while also becoming more efficient throughout our business. Because our balance sheet is strong, we're in an exceptionally good position to seize future growth opportunities and strengthen our standing in the markets where we currently operate. Before I go into the quarter's details, I want to take a minute to address where things stand on the flower supply-demand side. During the past year, demand for our flower products has risen rapidly after we gained market share in Canada and Israel. We've also seen further growth internationally, especially in Germany and the U.K. Because of that, we haven't been able to satisfy flower demand in full. In our view, what's driving this higher demand is a mix of our genetic breeding program and the cultivation capabilities at GrowCo. And with European growth accelerating and high-quality flower in short supply in Canada, we expect demand only to rise from here. That's why we announced the GrowCo expansion. This investment involved an additional credit facility of approximately $51 million to support expanding GrowCo's state-of-the-art production facility.

Mike Gorenstein

executive
#5

Through this investment, Cronos gained majority control of the Board and started consolidating GrowCo into our results during this quarter. As I've said previously, GrowCo's robust performance has been substantial, though underappreciated. These consolidated figures show a fuller view of our entire business. Moving now to brand news. During Q3, Spinach rose to the #1 ranked cannabis brand in the Canadian market, holding 4.8% market share, backed by #1 positions in edibles and flower, #4 in vapes and #8 in pre-rolls. The brand's market share outperformance reflects our unwavering dedication to quality, innovation and delivering differentiated products into the highly competitive Canadian adult-use market. Within the edibles category, SOURZ by Spinach, our industry-leading edibles, secured 17.2% of market share in Q3 and currently represents 5 of the top 10 best-selling edibles across Canada. Our emphasis on building innovative strategies and products in this category has been key to our success. We recently introduced our first seasonal offering, Caramel Green Apple SOURZ, which has been an enormous hit with consumers. During Q3, we also rolled out our Fully Blasted SOURZ in Ontario, a single 10-milligram THC gummy. That has become the fastest selling launch in company history. This quarter, we additionally launched new SOURZ flavors featuring rare cannabinoids.

Mike Gorenstein

executive
#6

The Strawberry Watermelon 4:1 gummy we offer, which contains CBG and THC, along with our Peach Passionfruit gummy featuring CBN, CBC (sic) CBD and THC, have both reached the market. Chocolate products under our Lord Jones brand are performing strongly too, rising fast to claim the third best-selling chocolate brand spot in Canada. We're eager to watch how Chocolate Fusions does over the holidays and as we move into winter, a period that typically brings a boost to the chocolate category. Spinach keeps up its outstanding results in flower, holding the #1 position across the Canadian market at 6% market share, powered by well-liked genetics including GMO cookies, Wedding Cake and Space Cake across multiple sizes. Our milled flower lineup, Spinach Grindz, has given this segment extra momentum as well. Our breeding program's ongoing wins, together with GrowCo, have reinforced where we stand in this category even further, guaranteeing premium quality and consistency. The vape category is still delivering stable results. Spinach holds the #4 spot at 6.4% market share. During this quarter, we introduced new Spinach HITZ all-in-one vapes in Pink Lemonade and Rocket Icicle, plus additional flavors, mango and grape, for 1.2 gram vapes. Our Pink Lemonade vape has become the #1 1.2 gram vape.

Mike Gorenstein

executive
#7

This is a fiercely competitive space, and we're dedicated to keep innovating and launching differentiated goods, flavors, and cannabinoid blends into the market. During this quarter, we observed market share gains within the pre-roll segment. For infused pre-rolls, Spinach recorded 25% growth in retail dollar sales, lifting our brand ranking to sixth position across all infused pre-roll brands. Lord Jones is emerging as an obvious frontrunner in hash-infused pre-rolls within Canada. The Sour Blueberry infused pre-roll, which we launched recently, finished Q3 as a top-selling hash-infused pre-roll. The infused pre-roll segment keeps expanding. That's why we're especially happy to be gaining ground here. We are intensely focused on enhancing and innovating our pre-roll lineup, and those signs of success are showing up in the numbers. Although there's still significant opportunity for growth in this area, we stay committed and confident regarding our expansion plans. Our approach has consistently been to build a portfolio of top-selling and disruptive branded products that we can introduce in new markets as cannabis regulations open up around the world. Spinach becoming the number-one selling brand in Canada confirms our strong capabilities, and we're only beginning to expand our winning portfolio of borderless products and deliver them to markets worldwide.

Mike Gorenstein

executive
#8

Turning now to Israel. Throughout Q3, the team there delivered outstanding results — record volumes sold and our strongest revenue quarter in 2 years. Despite a highly competitive market where patient growth has been declining, Cronos Israel has gained considerable momentum over the course of the year, and that speaks to the strength and quality of the PEACE NATURALS brand and products. Geopolitical factors have affected the region over this past year, yet we remain excited about growth in Israel, which gives us confidence in our position in this market. On the international side, we have made great strides in the markets we have entered. In Germany, our PEACE NATURALS brand keeps penetrating the market and growing at a strong clip. Given that we are selling the same products that led us to our #1 flower position in Canada, we are confident in the momentum we are seeing in the German market. We believe we have a right to win and are well positioned to continue to take share in the German market. Similarly, while it's early days in the U.K., we are starting to grow our PEACE NATURALS brand and are excited about our growth potential. This quarter's success — driven by our growing portfolio of borderless products, strong infrastructure and industry-leading balance sheet — enabled us to not only expand in our existing markets, but also to seize opportunities in any new market we choose to enter.

Mike Gorenstein

executive
#9

At this point, I'll hand things over to James, who will take you through the financials.

James Holm

executive
#10

Thanks, Mike, and good morning, everyone. I'll now walk through our results for the third quarter of 2024, which now reflect the consolidation of GrowCo's financials. Consolidated net revenue came in at $34.3 million for the company, up 38% compared with the same period a year earlier. Net revenue from Cronos, leaving out GrowCo, totaled $30 million, which works out to 21% growth year-over-year on a stand-alone basis, while GrowCo contributed $4.3 million in net revenue. The rise in net revenue was mainly fueled by stronger sales of cannabis flower and extracts in Canada, greater flower sales in Israel, and sales in other international markets, including Australia, Germany, and the U.K. Gross profit for the third quarter reached $3.6 million, which equates to an 11% gross margin. If we adjust for the inventory step-up stemming from the Cronos GrowCo transaction that was recorded within cost of sales, adjusted gross profit stood at $10.7 million, equal to a 31% adjusted gross margin. We'll keep providing this adjustment until the inventory that was stepped up to fair market value through the purchase accounting adjustment has been fully sold through, since we believe it helps when reviewing and evaluating our ongoing performance. Adjusted gross profit improved by $6.8 million year-over-year, and adjusted gross margin rose by 15 percentage points.

James Holm

executive
#11

That rise came mainly from stronger cannabis flower and extract sales in Canada, along with greater cannabis flower sales in Israel and revenue from other international markets. For the third quarter, consolidated adjusted EBITDA stood at negative $6 million, which is a $9.2 million improvement over the prior year period. That gain came from higher net revenue and lower general and administrative expenses. The rigorous OpEx discipline we've applied so far has us well on track toward our 2024 target of an incremental $5 million to $10 million in savings for Cronos on a stand-alone basis, and we're tracking toward the high end of that range. That said, bringing GrowCo's OpEx into our consolidated financials is expected to offset those savings next year. Moving to the balance sheet and cash flow: the company finished the quarter with $862 million in cash and cash equivalents. That figure rose $14 million from Q2, mainly because of better cash flow from operations and some FX fluctuations. Cash flow from operations was positive $11.6 million versus a negative $0.2 million in the prior year period, and free cash flow came in at positive $5 million versus a negative $0.5 million in the prior year period, thanks to an increase in adjusted gross profit and an income tax refund — a significant improvement.

James Holm

executive
#12

Reflecting on how far we’ve come, I share Mike’s confidence in where our business is heading and in how ready we are to enter new markets as they open up. With that, I’d like to give it back to Mike for a quick comment before we move into Q&A.

Mike Gorenstein

executive
#13

To wrap up, this quarter's achievements set a new high, and that makes us proud. The approaches we've put in place are producing outcomes, and as we finish the year we stay dedicated to extending that momentum. We will keep pushing revenue growth, strengthening margins, and broadening our footprint abroad, which sets Cronos up for success over the long term. With that said, I'll hand things over for questions.

Operator

operator
#14

<<operator_script>> The initial question will be taken from Matt Bottomley at Canaccord Genuity.

Matt Bottomley

analyst
#15

Mike, I’d like to begin. I realize this isn’t truly core to the business, but I know you’ve had long-standing — considerable long-standing experience and expertise in, sort of, the U.S. sector. I’m just curious about your views after the election. You clearly have a very strong balance sheet, potentially one day, if opportunities arise down south. And I’m just curious, given how these equities have responded and the change in administration, whether you have any takeaways on where you see the U.S. heading over the next year or so?

Mike Gorenstein

executive
#16

Thanks, Matt. That's a really good question. I think there remains some uncertainty over the coming couple of weeks as we watch the transition team assemble and see what that could mean. But broadly speaking, I think as a matter of policy, an incoming administration frequently pulls back and restarts all the pending regulatory rules. Our understanding is that the Trump administration backs the STATES Act. And I think that's still a positive thing. But at a minimum, I would expect the rescheduling efforts to sort of restart the clock. So if anything happens at all, Schedule III, I think, is about 18 months away, if rescheduling is going to occur. But we believe that building on the STATES Act and on some of the existing hemp frameworks is the way forward. Big picture, what I'll say is that I think we're actually now in a very good position where we don't need to rely on that regulatory change given the growth we're seeing in Canada, Israel and the regulatory tailwinds in Europe and growth there.

Matt Bottomley

analyst
#17

Alright, that's interesting — I've got it. Now, moving a bit further into the Cronos side of things. So yes, it was interesting to hear some of what you said about the dynamics you're observing with your own branded flower and with some of the genetics. I know you have differentiation in that part of the market, but it's been a very, very long time since we've heard about LPs expanding capacity. So I'd like to understand the risk/reward there and how that's specific to the Cronos model compared with what we've observed over the last couple of years — which has been some fairly ugly supply-demand dynamics for perhaps lower-grade flower.

Mike Gorenstein

executive
#18

Yes. So I think we're lucky in that, early on, much of our attention went toward genetic breeding, consumer insights, and broadly R&D on cultivation methods. Flower demand has been climbing steadily, in our view. As a result, we hold SKUs that rank at the top in Canada and Israel. Momentum in Europe looks really strong. And I think we're now at a point where we must choose which markets to fill. That's Cronos by itself. I think there's also considerable demand from other LPs from GrowCo, but we believe we'd be doing much better in flower with more supply, and that applies really across markets. So I think if we keep our focus on quality, the model of having GrowCo produce the genetics that we have in market and the pipeline of genetics we have, which we're really excited about, should keep driving that success.

Operator

operator
#19

Bill Kirk from ROTH has our next question.

Bill Kirk

analyst
#20

This ties into what you just said, Mike. Regarding GrowCo, how should we think about seasonality in that business—both for the top line contribution and for profitability contribution, now that you're consolidating it? How should we think about seasonality going forward? And then, how do you decide resource allocation between your own needs and third-party needs? How is that worked out so you get what you want while also selling to the customers who need it as well?

Mike Gorenstein

executive
#21

Sure, and thanks — that's a really good question. I'd say there honestly isn't much seasonality when it comes to the top line, particularly with the shortage and where things stand right now. There are some minor variations in terms of which seasons are most efficient for production — how much power you have to draw for supplemental lighting as opposed to heating and cooling. Summer sometimes turns out not to be the ideal season for cultivation. But given how high-tech the greenhouse is, things stay fairly even overall, and a difference is pretty tough to spot. Then more broadly, the way we structured the deal, we hold an option rather than an obligation. Before the second phase comes online, we're able to buy as much as 80% of the supply at a preset price. And after the second phase comes online, that would grow today's current capacity by 70%. We have an option rather than an obligation to purchase as much as 70% at a preset price. So we see it as a really solid balance, where we can ensure we're only filling demand that we believe exists and that fits the brand, while there's still meaningful upside compared with where we are today.

Bill Kirk

analyst
#22

All right. Maybe I missed this in the prepared remarks, but it seems like CapEx spending took a step up this quarter compared with the levels it had been at. What's driving that? Perhaps I ought to know this already, but what's behind it? And does it point to any kind of shift in your intentions for how you use capital?

James Holm

executive
#23

The main driver behind that CapEx was really the GrowCo Phase 2 expansion. In Q3, we spent about $6.5 million on CapEx. As that expansion continues, we'd expect CapEx levels to rise until it's complete. That's really the primary factor there.

Bill Kirk

analyst
#24

And if we look at it on a quarterly basis, roughly in line with 3Q? And what was the overall CapEx expectation, kind of, for that second phase?

James Holm

executive
#25

Yeah. So Mike touched on that a bit earlier, but at least we've given them roughly USD 51 million, right? It might come in a little below that. But my expectation is that some of it could be fairly even — or it could be somewhat lumpy, right, across the coming few quarters. We do expect that extra biomass to be online in the second half. So hopefully around midyear is when the CapEx spending for Phase 2 would wrap up, if that helps.

Operator

operator
#26

That's all the questions we have right now. Thanks for joining today's conference. That brings the program to a close. You can disconnect at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Cronos Group Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

For developers and AI pipelines

Programmatic access to Cronos Group Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cronos Group Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.